-
CUDA 2026 | Prof. Xiaoying Li: From Technological Innovation to MDT Collaboration—Redefining the Landscape of Urologic Oncology
The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou from June 11–14, bringing together leading experts in urology and related disciplines under the theme “Unity, Collaboration, Innovation, and Development.” The meeting focused on advancing high-quality clinical research, technological innovation, multidisciplinary collaboration (MDT), and regional cooperation, while promoting the continued development…
-
BOC 2026 | Prof. Pei Dong: Kidney Cancer Enters the Era of Long-Term Survival, with New Advances in Adjuvant Therapy and Comprehensive Disease Management
In renal cell carcinoma (RCC), continued advances in targeted therapy and immunotherapy have ushered patients with advanced disease into an era of long-term survival and chronic disease management. However, important clinical challenges remain, including optimizing adjuvant treatment for high-risk patients after surgery, selecting effective therapies following immunotherapy resistance, and developing multidisciplinary models for comprehensive care…
-
BOC 2026 | Prof. Wasilijiang-Wahafu: Neoadjuvant Therapy for MIBC Enters a New Era with Precision Stratification and Comprehensive Perioperative Management
In recent years, the perioperative management of muscle-invasive bladder cancer (MIBC) has undergone rapid transformation. The emergence of immunotherapy, antibody-drug conjugates (ADCs), and precision biomarker-driven treatment has fundamentally reshaped the therapeutic landscape.
-
CUDA 2026 | Prof. Nianzeng Xing: Advancing Urology Through Collaboration and Innovation
The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou from June 11–14, 2026. As one of China’s most influential national academic meetings in urology, this year’s conference adopted the theme “Collaboration and Innovation”, bringing together leading domestic and international experts to discuss advances in minimally invasive surgery, robotic technology, precision…
-
CUDA 2026 | Rethinking Tiered Healthcare and Multidisciplinary Care in Urology—An Interview with Prof. Zhisong He
The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou under the theme “Collaboration and Innovation.” The conference focused on key topics including precision diagnosis and treatment of urologic diseases, comprehensive cancer management, and multidisciplinary team (MDT) care, showcasing China’s latest advances in technological innovation and the standardization of clinical practice.
-
CUDA 2026 | Prof. Xingyuan Xiao: Rethinking Comprehensive Urologic Cancer Management Through the Integration of Traditional Chinese and Western Medicine and MDT
The 2026 Annual Meeting of the Chinese Urological Doctor Association (CUDA 2026) was held in Zhengzhou, Henan, from June 11 to 14. Prof. Xingyuan Xiao of Zhongnan Hospital of Wuhan University has long been engaged in the clinical management and research of urologic diseases, with extensive experience in integrating traditional Chinese medicine (TCM) and Western…
-
CUDA 2026 | Prof. Zhaohui Gu: Advancing Intelligent Surgery and Precision Treatment to Shape the Future of Urology
The 2026 Annual Meeting of the Chinese Urological Doctor Association (CUDA 2026) was held in Zhengzhou from June 11 to 14. As one of China’s most influential national academic meetings in urology, this year’s congress highlighted cutting-edge developments in robotic surgery, AI-assisted diagnosis and treatment, precision medicine, and minimally invasive technologies, promoting clinical translation and…
-
Breaking New Ground in Oligometastatic Kidney Cancer | Prof. Liru He’s Team Reports Sunitinib Plus SBRT Strategy in Cell Reports Medicine
The treatment landscape for renal cell carcinoma (RCC), one of the most common malignancies of the urinary system, continues to evolve rapidly, with targeted therapy combined with immunotherapy now established as a standard first-line approach for advanced and metastatic disease. However, for patients with oligometastatic RCC, a standardized treatment strategy has yet to be established.
Connecting Medical Expertise through Media